Meticulous Research®, a renowned global market research firm, has published a comprehensive report titled, "Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (mAb, Vaccine), Research], End User – Forecast to 2030." According to this report, the Europe single-use bioreactors market is forecasted to reach $3.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 15.3% over the forecast period. Key factors driving this robust growth include the increasing adoption of disposable technologies in the pharmaceutical and biotechnology industries, biopharmaceutical plant expansions, rising R&D expenditures in the pharmaceutical sector, growing adoption of biosimilars, and the prevalence of chronic diseases, especially among the aging population.
Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5552
Market Overview and Segmentation
The Europe single-use bioreactors market is divided into various segments based on product, type, cell type, application, end user, and geography. The report provides in-depth insights into these categories, offering a thorough analysis of market trends and drivers for each segment.
- Product Segmentation
The market is categorized into single-use bioreactor systems, media bags, filtration assemblies, and other products. Among these, the single-use bioreactor systems segment is expected to dominate in 2024. This dominance is driven by several advantages that single-use systems offer, including reduced cleaning requirements, greater operational flexibility, a smaller physical footprint, and lower capital investment needs. In addition, these systems mitigate the risk of cross-contamination, which is a significant concern in biopharmaceutical production. The increasing demand for cost-efficient solutions in biopharma, coupled with vendors focusing on large-scale bio-manufacturing, has further fueled the adoption of single-use bioreactor systems.
- Type Segmentation
The market is also segmented by type, which includes stirred-tank, wave-induced, and other types of bioreactors. In 2024, stirred-tank bioreactors are anticipated to account for the largest share of the market. These bioreactors are widely used for culturing Chinese Hamster Ovary (CHO) cell lines and suspension cultures in large-scale bio-production processes. Stirred-tank bioreactors' modern design, which surpasses traditional systems in terms of efficiency and scalability, has made them a preferred choice for many biopharmaceutical manufacturers.
- Cell Type Segmentation
The Europe single-use bioreactors market is segmented by cell type into mammalian cells, bacterial cells, yeast cells, and other cell types. Mammalian cells are projected to hold the largest market share in 2024. Mammalian cells are commonly used in bioproduction, especially in the development of complex biomolecules such as monoclonal antibodies and therapeutic proteins. They are also widely used in clinical research due to their ability to model human biological processes more accurately. This extensive use in both commercial production and research applications is a significant factor behind the market dominance of mammalian cells.
Browse In Depth: https://www.meticulousresearch.com/product/europe-single-use-bioreactors-market-5552
- Application Segmentation
Based on application, the market is divided into commercial bioproduction and research bioproduction. The commercial bioproduction segment is expected to dominate in 2024. The growth of this segment is driven by the increasing production of biosimilars, the rising prevalence of genetic and rare diseases, and government support for vaccine production and immunization programs. As biopharmaceutical companies ramp up production to meet growing demand, single-use bioreactors offer an efficient solution for commercial bioproduction due to their flexibility and scalability.
- End-user Segmentation
The end users of single-use bioreactors include pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and academic and research institutes. Among these, the CDMOs and CROs segment is expected to witness the highest CAGR during the forecast period. The growth of this segment can be attributed to several factors, including increased outsourcing by pharmaceutical and biopharmaceutical companies to CDMOs and CROs, key players' preference for inorganic growth strategies, and expansion initiatives by CDMOs. A notable example is the July 2021 opening of Viralgen VC’s new manufacturing facility in Basque, Spain, which is dedicated to adeno-associated virus gene therapy production.
Regional Analysis
The report also provides a comprehensive geographical analysis, focusing on major European markets, including Germany, France, the U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and the Rest of Europe. In 2024, Germany is expected to lead the Europe single-use bioreactors market, holding the largest market share. Several factors contribute to Germany's dominance, including rising drug sales, support from government and regulatory bodies for biopharmaceutical production, and the expansion of manufacturing capacities by various companies. Germany's biopharmaceutical industry is well-established and continues to grow, bolstered by favorable policies and investments in cutting-edge technologies such as single-use bioreactors.
Key Players in the Market
The competitive landscape of the Europe single-use bioreactors market is characterized by the presence of several leading companies. Key players profiled in the report include:
- Merck KGaA (Germany): A prominent player in the life sciences industry, Merck KGaA offers a broad range of products and services, including single-use bioreactors for biopharmaceutical production.
- Danaher Corporation (U.S.): This multinational conglomerate operates through its subsidiary, Pall Corporation, which provides biopharmaceutical companies with innovative single-use technologies.
- Sartorius AG (Germany): A global leader in bioprocess solutions, Sartorius AG is a key player in the single-use bioreactors market, offering scalable systems for both research and commercial production.
- Thermo Fisher Scientific Inc. (U.S.): This American company offers a wide range of single-use bioprocessing technologies, including bioreactors, for use in pharmaceutical and biotechnology applications.
- Eppendorf AG (Germany): Known for its laboratory equipment, Eppendorf AG provides single-use bioreactors tailored to small- and mid-scale bioproduction.
- Solaris Biotechnology srl (Italy): This Italian company specializes in bioprocessing technologies, offering innovative single-use bioreactor systems for various applications.
- Cellexus International Ltd. (U.K.): A U.K.-based company providing single-use bioreactors designed for cell culture and fermentation processes.
- CESCO Bioengineering Co., Ltd. (Taiwan): A significant player in the bioprocessing market, CESCO Bioengineering focuses on providing scalable solutions for biopharmaceutical production.
- PBS Biotech, Inc. (U.S.): Known for its unique single-use bioreactors, PBS Biotech offers scalable systems that cater to various biopharmaceutical production needs.
- Solida Biotech GmbH (Germany): This German company offers single-use bioreactor systems designed for flexibility and efficiency in bioprocessing applications.
- Infors AG (Switzerland): A Swiss company offering a range of bioprocessing technologies, including single-use bioreactors, for research and industrial applications.
Quick Buy – Europe Single-use Bioreactors Market –Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/77071228
Conclusion
The Europe single-use bioreactors market is poised for significant growth in the coming years, driven by increasing adoption across the biopharmaceutical industry. The market's expansion is fueled by the need for cost-effective, flexible, and scalable solutions to meet rising demand for biologics, biosimilars, and vaccines. With key players continuously innovating and expanding their offerings, the market is set to evolve rapidly, offering lucrative opportunities for stakeholders across the value chain.
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
